Amarin (AMRN +1%) gets a boost from some positive commentary out of Leerink Swann today, saying...

|About: Amarin Corporation PLC (AMRN)|By:, SA News Editor

Amarin (AMRN +1%) gets a boost from some positive commentary out of Leerink Swann today, saying that Vascepa's prescription data appears to be tracking well. The firm notes that the largest TRx advance since the drug's launch was recorded last week, and the number of new prescriptions and refills are growing. Looking forward, Leerink thinks the AMRN's ramped-up marketing efforts and moves to obtain Tier 2 reimbursement should further accelerate TRx growth.